The projected U.S. market for biodefense-related rapid pathogen detection devices is expected to reach $364 million by 2021.
Wellesley, Mass. (PRWEB) August 14, 2015
Demand for point-of-use devices will accelerate the growth of handheld devices in the U.S. market for biodefense-related rapid pathogen identification and treatments. BCC Research reveals in its new report that the majority of devices used for rapid detection are handheld readers with the ability to read various assays, either by individual pathogen or with several pathogens in one test.
The U.S. market for rapid identification/sensing products is projected to grow from $248 billion in 2016 to $364 billion in 2021, reflecting a five-year compound annual growth rate of 8%.
The report outlines the political and social landscape of biodefense, focusing on the issues of surveillance, coordination of resources and financing. Additionally, government funding, as well as industry and university funding of biodefense projects, is discussed.
Pathogenic agents can be viruses, bacteria, fungi, protozoa, parasites, or manufactured toxins. They are able to cause diseases in plants, animals and humans. Pathogens that are harmful to animals and plants are not covered in this report unless they pose eminent danger to humans through consumption.
The market for biodefense-related rapid pathogen identification products continues to expand with an emphasis on products that are more portable, easy to use, sensitive and accurate. Multiple assays are being field-tested and used by military personnel, first responders, industry and businesses.
“The need for rapid identification has expanded the market for handheld assay devices that can accurately determine if a pathogen is present and its composition,” says BCC Research analyst Peggy S. Lehr. “Evolving technology can determine the amount of pathogen present. The handheld assay market holds the largest share of the detection market, followed by portable units and then stationary units.”
The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments (BIO145A), which focuses on the U.S. biodefense-related rapid pathogen identification and treatment markets, provides an overview of the industry and its participants. It also projects the growth of the market through 2021, with analysis of trends and emerging technologies pertinent to biological rapid pathogen identification.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven(dot)cumming(at)bccresearch(dot)com.
About BCC Research
BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years we've helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key market participants. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Recently selected as the world’s greatest market research company, BCC Research is a unit of Eli Global, LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or email information(at)bccresearch(dot)com.